MedTrace Logo

Safety and Efficacy Study of the Effect of Etanercept in Hemodialysis Patients

NCT00293202 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2021-07-13

Study results available
· View outcomes & findings →

Summary

Etanercept is a novel anti-inflammatory agent currently used in patients with rheumatoid arthritis. We are examining whether Etanercept is effective in improving the nutritional status of hemodialysis patients as a consequence of its ability to decrease inflammation.

Conditions

Interventions

DRUG

Etanercept

Hemodialysis patients will receive Etanercept at a dose of 25 mg by subcutaneous injection twice a week

DRUG

Placebo

Hemodialysis patients will receive Saline by subcutaneous injection twice a week

Sponsors & Collaborators

  • Amgen

    collaborator INDUSTRY

  • Dialysis Clinic, Inc.

    collaborator INDUSTRY

  • Kaysen, George A., M.D., Ph.D.

    lead OTHER

Principal Investigators

  • George Kaysen, MD, PhD · University of California, Davis

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-01-31
Primary Completion
2008-03-31
Completion
2010-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00293202 on ClinicalTrials.gov